Login to Your Account



A SLICE OF JAKAFI PIE?

‘Marrowing’ the gap: CTI starts another pacritinib phase III in MF

By Randy Osborne
Staff Writer

Tuesday, March 4, 2014
Bolstering its phase III push with the JAK2/FLT3 inhibitor pacritinib in the heating-up myelofibrosis (MF) space, Cell Therapeutics Inc. (CTI) began Persist-2, a study in patients with the disease and platelet counts less than or equal to 100,000 per microliter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription